Back to search

Peptide record

TPDB92384

At9 Antibacterial Anticancer Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92384
At9
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0
standard
No
A 15-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-KVVKKVKKKVKKVVK-NH2
Physicochemical Analysis
C84H164N24O16
ARNDCEQGHILMFPSTWY
K
1766.38
11.41
9
0
6
+9
9.33
-0.660
116.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
9
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
6
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 9 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 6
Chemical Descriptors
15
C84H164N24O16
1766.38
11.41
+9
9.33
-0.660
Amidation
L
Linear
Acetylation
Antimicrobial
Synthetic
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 100 µM
Anticancer
100 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 51.7 µM
Anticancer
51.7 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022